Business · 04/08/2025Updated: 10/17/2026 · 1 min read
FDA Clears Heparin Sodium Products for Approval of Abbreviated New Drug Applications
Summary
The FDA has determined that three Heparin Sodium products were not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications for these products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →